Onconetix, Inc. (ONCO)
- Previous Close
0.1204 - Open
0.1200 - Bid --
- Ask --
- Day's Range
0.1150 - 0.1220 - 52 Week Range
0.1000 - 1.5800 - Volume
159,244 - Avg. Volume
659,167 - Market Cap (intraday)
2.601M - Beta (5Y Monthly) 3.38
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 12, 2024 - May 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
onconetix.gcs-web.comRecent News: ONCO
Performance Overview: ONCO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONCO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONCO
Valuation Measures
Market Cap
2.60M
Enterprise Value
7.93M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
34.10
Price/Book (mrq)
--
Enterprise Value/Revenue
135.68
Enterprise Value/EBITDA
-0.22
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.44%
Return on Equity (ttm)
-314.47%
Revenue (ttm)
58.47k
Net Income Avi to Common (ttm)
-37.41M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
4.55M
Total Debt/Equity (mrq)
703.88%
Levered Free Cash Flow (ttm)
-16.09M
Research Analysis: ONCO
Company Insights: ONCO
ONCO does not have Company Insights